New experts strengthen NHG’s pharma team

News

September 17, 2021

Helena Henno (left) and Outi Isomeri (right)

Two new experienced professionals, Senior Managers Helena Henno and Outi Isomeri joined Nordic Healthcare Group (NHG) in August. A warm welcome!

Helena Henno holds two Masters degrees: one in health and biotechnology and the other in industrial engineering with focus on strategy and leadership. Previously, she worked at VTT Technical Research Centre of Finland as a researcher in immunodiagnostics and, since 2016, as a consultant and project manager att MedEngine with focus on pharma, health tech and biobanks. Helena brings valuable insight on into combining research and design for the pharma and health tech sectors as well as for health and social care organisations.

”I’m excited to be at the core of health and social care and to be able to draw on my previous, diverse experience. Thinking patient-focused is close to my heart: the patient and customer are always at the center of services regardless of the service or it’s provider. At NHG, I feel that I’m doing meaningful work by helping to improve health and social care in the Nordics,” she commented.

Outi Isomeri has profound and diverse experience in the fields of medicine and health care. Before joining NHG, she worked in consulting, in the pharmacy industry and in pharma companies. Outi was a customer and HR manager in the pharmacy industry and, since 2017, she worked for Medaffcon in healthcare and pharma consulting with focus on the different areas within the pharma industry, i.e., medical, market access, care pathways, and RWD. From consulting, she went over to international oncology start up Tesaro focusing on gynecological cancers. At Tesaro, she acted as a medical expert in the Nordics and supported the market access in Finland. In 2020, Tesaro became through acquisition part of GSK where Outi continued as an expert in oncology in Finland. Outi has both a Masters in pharmacy as well as industrial engineering with focus on health economics and healthcare analytics.

“Now and in the future, recoverability of medicines and getting new medicines on the market is a challenge needing innovations. I believe we at NHG can support pharma companies in this a great deal. Cost-efficiency and health benefits are vital to both medication and the entire field of health and social care. Finland is an excellent country for research. I want to help pharma companies to get more clinical and registry research to Finland and, at the same time, promote the potential of Finland and the Nordics globally,” she commented.

”I’m glad that we now have two new experienced experts at NHG. Helena and Outi have holistic experience which combines understanding the needs of pharma companies and patients. This expertise is vital to us as NHG invests on services for the pharma industry in the Nordics,” commented NHG’s Group CEO Vesa Kämäräinen.